Acquired by R-Biopharm
Industries BiotechnologyLife ScienceOncologyProduct ResearchHeadquarters Regions European Union (EU), Europe, Middle East, and Africa (EMEA) Founded Date 2009 Operating Status Active
Company Type For Profit
Phone Number +498974419166
GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology. We specialize in biomarker prescreening for patient stratification to ensure the best possible care for cancer patients. By employing bioinformatical algorithms based on knowledge in pathway structure and microarray data from public sources, it is
possible to limit biomarker screening to analysis on a low-density scale. This is not only cost efficient, but also more easily interpreted compared to high-density
methods like whole genome microarrays. Samples can be anything from fresh frozen or paraffin embedded tissue to whole blood. A typical output of a study would be a short list of 10-20 potential biomarkers, that are highly likely to carry changes on the DNA or protein level.
Transaction Name GeneWake GmbH acquired by R-BiopharmAcquired by R-BiopharmAnnounced Date Oct 13, 2015